摘要
NKG2D受体是一种表达于多种免疫细胞表面的激活型受体.目前发现与它结合的配体有8种,可以分为两大类：MHCⅠ类相关蛋白和UL16结合蛋白.NKG2D受体与其配体差异存在于正常组织与癌组织中.多项研究发现,NKG2D受体介导免疫细胞杀伤肿瘤,在机体抵抗肿瘤的发生发展中起到不可替代的作用.“过继免疫”通过寻找针对癌细胞有特异杀伤作用的免疫细胞并扩增其数量后输入体内,用于癌症的治疗.近年来学者们发现,DNT细胞（CD4 CD8-T细胞）对癌细胞有明显的杀伤作用,但具体机制尚不清楚,本文在总结NKG2D受体介导的杀伤通路的基础上,探讨、分析其与DNT细胞杀伤作用的关联性,目的在于研究DNT细胞的杀伤机制.
NKG2D is an activating receptor expressed on various immune cells＆#39; surfaces.Currently,eight ligands have been found,they can be divided into two kinds：MHC Ⅰ related protein and ULBP molecules.NKG2D receptors and their respective ligands differentially exist in normal and cancerous tissues.So far,many researchers have found that a lot of immune cells＆#39; anti-tumor mechanism is mediated by NKG2D receptor and it can＆#39;t be replaced in the resistance to the development of carcinoma.＆quot;adoptive immunotherapy＆quot; is a new method of treating cancer that propose to find tumor-specific cytotoxicity immune cells and enlarge the amount of it,then injected into human body to resist tumor.Recently,many researchers have found that DNT cells （CD4-CD8-T 细胞）have the function of anti-tumor;sadly its mechanisms are unclear.After the summary of NKG2D receptor-mediated pathway of destruction,this paper try to analyze its relevance to DNT cells＆#39; killing effect,on the purpose of finding the Killing mechanism of DNT cells that may existed.
出处
《国际外科学杂志》
2015年第6期429-432,共4页
International Journal of Surgery
基金
国家自然科学基金（No.81071985）
安徽省国际科技合作项目（No.10080703038）
